{{Chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444599209
| ImageFile = Niperotidine.svg
| ImageSize = 300
| IUPACName = (''Z'')-1-''N&prime;''-(1,3-Benzodioxol-5-ylmethyl)-1-''N''-[2-<nowiki>[[</nowiki>5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-2-nitroethene-1,1-diamine
| OtherNames =

| Section1 = {{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 12JBD7U72K
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 84845-75-0
| PubChem = 3033952
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07072
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1909284
| SMILES = CN(C)Cc1ccc(o1)CSCCN/C(=C\[N+](=O)[O-])NCc2cc3OCOc3cc2
| EINECS = 284-304-0
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 11644617
| InChI = 1/C20H28N4O5S/c1-23(2)11-16-4-5-17(29-16)13-30-8-7-21-20(12-24(25)26)22-10-15-3-6-18-19(9-15)28-14-27-18/h3-6,9,20-22H,7-8,10-14H2,1-2H3
| InChIKey = VZPXHGJTEAPNAA-UHFFFAOYAQ
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C20H28N4O5S/c1-23(2)11-16-4-5-17(29-16)13-30-8-7-21-20(12-24(25)26)22-10-15-3-6-18-19(9-15)28-14-27-18/h3-6,9,20-22H,7-8,10-14H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = VZPXHGJTEAPNAA-UHFFFAOYSA-N
| RTECS = 
| MeSHName = C073716
 }}

| Section2 = {{Chembox Properties
| C=20
| H=26
| N=4
| O=5
| S=1
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility = 
 }}

|Section6 = {{Chembox Pharmacology
| ATCCode_prefix = A02
| ATCCode_suffix = BA05
}}

|Section7 = {{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt = 
 }}
}}

'''Niperotidine''' is a [[histamine antagonist]] selective for the [[Histamine H2 receptor|H<sub>2</sub>]] subtype. It was studied as a treatment for excessive gastric acidity,<ref>{{cite journal | pmid = 1983712| year = 1990| author1 = Palasciano| first1 = G| title = The effect of the H2-antagonist niperotidine on intragastric acidity in healthy subjects undergoing 24-hour pH-monitoring| journal = The Italian journal of gastroenterology| volume = 22| issue = 5| pages = 291–4| last2 = Maggi| first2 = V| last3 = Portincasa| first3 = P}}</ref> but withdrawn after human trials showed [[hepatotoxicity|liver damage]].<ref>{{cite journal | pmid = 9314138| year = 1997| author1 = Gasbarrini| first1 = G| title = Acute liver injury related to the use of niperotidine| journal = Journal of hepatology| volume = 27| issue = 3| pages = 583–6| last2 = Gentiloni| first2 = N| last3 = Febbraro| first3 = S| last4 = Gasbarrini| first4 = A| last5 = Di Campli| first5 = C| last6 = Cesana| first6 = M| last7 = Miglio| first7 = F| last8 = Miglioli| first8 = M| last9 = Ghinelli| first9 = F| last10 = d'Ambrosi| first10 = A| last11 = Amoroso| first11 = P| last12 = Pacini| first12 = F| last13 = Salvadori| first13 = G}}</ref>

==References==
<references/>

{{Histaminergics}}
{{Drugs for peptic ulcer and GORD}}

[[Category:Abandoned drugs]]
[[Category:Amines]]
[[Category:Benzodioxoles]]
[[Category:Furans]]
[[Category:H2 receptor antagonists]]
[[Category:Nitroethenes]]
[[Category:Thioethers]]

{{gastrointestinal-drug-stub}}